ADORA2B抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P12139(ADORA2B Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12139(ADORA2B Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The ADORA2B antibody targets the adenosine A2B receptor, a G-protein-coupled receptor (GPCR) that binds adenosine, a purine nucleoside involved in cellular energy homeostasis and signaling. ADORA2B, encoded by the ADORA2B gene, is one of four adenosine receptor subtypes (A1. A2A, A2B, A3) and is distinguished by its lower affinity for adenosine compared to A1 and A2A. It couples primarily to Gs proteins, activating adenylyl cyclase to increase intracellular cAMP, though it may also engage Gq-mediated pathways under certain conditions.

ADORA2B is widely expressed in vascular endothelial cells, immune cells (e.g., mast cells, macrophages), and the central nervous system. It plays roles in vasodilation, inflammation, hypoxia adaptation, and fibrosis. Research highlights its involvement in pathological conditions such as ischemic injury, chronic lung diseases, and cancer progression, where it modulates immune responses and angiogenesis.

ADORA2B antibodies are essential tools for studying receptor localization, expression levels, and signaling mechanisms. They are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to explore ADORA2B's functional contributions in disease models. Recent studies also investigate its potential as a therapeutic target, with antagonists or agonists being explored for treating inflammatory disorders, cardiovascular diseases, or cancer. Validated ADORA2B antibodies typically exhibit specificity for human, mouse, or rat isoforms, enabling cross-species translational research.